Paradigm Biopharmaceuticals Limited (ASX: PAR) - Share Price
Current share price for PAR : $0.175 0.005 (2.78%)+
Paradigm Biopharmaceuticals Ltd. (PAR) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is engaged in researching and developing therapeutic products for human use.
PAR General Information +
| ASX Code | PAR |
| Website | http://www.paradigmbiopharma.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 104 |
| PAR Share Price | $0.175 |
| Day High | $0.180 |
| Day Low | $0.175 |
| Last Close | $0.180 |
| PAR Share Price Movement | $0.01 ( 2.78% ) |
Prices as at 16:40, 7 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Paradigm Biopharmaceuticals Limited (PAR) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Paradigm Biopharmaceuticals Limited (PAR) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Paradigm Biopharmaceuticals Limited (PAR) price-sensitive announcements
PAR - June 2026 Quarterly Activities Report & Appendix 4C
Paradigm Biopharmaceuticals Ltd. highlighted significant progress in its Phase 3 osteoarth
Paradigm Biopharmaceuticals Limited (PAR)
30 Jul 2026 | 9:55 AM
30 Jul 2026 | 9:55 AM
PAR - Paradigm Receives $5.75m R&D Tax Incentive Refund
Paradigm Biopharmaceuticals Limited has bolstered its financial position by securing a tot
Paradigm Biopharmaceuticals Limited (PAR)
22 Jul 2026 | 8:18 AM
22 Jul 2026 | 8:18 AM
PAR - Drawdown of Tranche 4 under the Convertible Note Facility
Paradigm Biopharmaceuticals Ltd. has completed the drawdown of Tranche 4 valued at US$3 mi
Paradigm Biopharmaceuticals Limited (PAR)
13 Jul 2026 | 1:14 PM
13 Jul 2026 | 1:14 PM
PAR - PAR Completes Enrolment in Pivotal Phase 3
Paradigm Biopharmaceuticals Ltd. has successfully completed enrolment for its pivotal Phas
Paradigm Biopharmaceuticals Limited (PAR)
15 Jun 2026 | 9:11 AM
15 Jun 2026 | 9:11 AM
Paradigm Biopharmaceuticals Limited (PAR) Recent ASX Announcements
PAR Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$16.24 | -$5.20 | -74.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$58.65 | -$20.00 | 11.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$52.00 | -$18.00 | 10.20% | 0.00 | 0.00 | 0.00% | 0.0% |
PAR Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| CSL Limited (CSL) | $63,389M | 0.1108 | -0.1218 | 0.0167 | 14.1930 | 16.1620 | 15.8962 | 3.37% | 2.75% | 2.86% |
| Clinuvel Pharmaceuticals Limited (CUV) | $473M | 0.0287 | 0.0000 | 0.0000 | 13.0501 | 0.0000 | 0.0000 | 0.53% | 0.00% | 0.00% |
| Mesoblast Limited (MSB) | $2,896M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Paradigm Biopharmaceuticals Limited (PAR) | $108M | -0.7420 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $5,110M | -1.3893 | 0.0000 | -0.1431 | 0.0000 | 247.3684 | 288.6756 | 0.00% | 0.00% | 0.00% |
PAR Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 3.22 | 0.00 |
| Market | 0.31 | 13.10 | 1.15 | 0.65 |
| Sector | 0.49 | 33.50 | 2.47 | 2.59 |
PAR Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Paul Rennie | Executive Director, Managing Director, Executive Chairman | 2 May 2014 |
| Mr Amos Meltzer | Non-Executive Director | 9 Dec 2020 |
| Mr Matthew James Fry | Non-Executive Director | 4 Mar 2024 |
Paradigm Biopharmaceuticals Limited (PAR) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 2 Jun 2026 | RENNIE, Paul | Buy | Direct Shares | 176,470 | $0.170 | $30,000.000 |
| 2 Jun 2026 | RENNIE, Paul | Buy | Indirect Shares | 352,940 | $0.170 | $60,000.000 |
| 2 Jun 2026 | FRY, Matthew | Buy | Indirect Shares | 176,470 | $0.170 | $30,000.000 |
See all changes in directors' interest & trades for Paradigm Biopharmaceuticals Limited (PAR) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
PAR Management
| Name | Position |
|---|---|
| Abby Macnish | Interim Company Secretary |
PAR Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Paradigm Biopharmaceuticals Limited (PAR). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 20,726,750 (5.32%) | Paul Rennie and related companies |
| 20,216,245 (5.19%) | Citicorp Nominees Pty Limited |
| 14,090,211 (3.61%) | HSBC Custody Nominees (Australia) Limited |
PAR Calendar of Events
| Date | Event |
|---|---|
| 26 February 2027 | Report (Interim) |
| 28 August 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
